Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
19.96
-0.15 (-0.75%)
At close: Dec 5, 2025, 4:00 PM EST
19.70
-0.26 (-1.30%)
After-hours: Dec 5, 2025, 7:26 PM EST
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 32.67, with a low estimate of 26 and a high estimate of 42. The average target predicts an increase of 63.68% from the current stock price of 19.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 6 | 7 |
| Buy | 7 | 7 | 8 | 8 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 16 | 16 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $30 → $31 | Buy | Maintains | $30 → $31 | +55.31% | Dec 5, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +60.32% | Dec 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $24 → $26 | Buy | Maintains | $24 → $26 | +30.26% | Nov 4, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 8, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $33 → $30 | Buy | Maintains | $33 → $30 | +50.30% | Aug 18, 2025 |
Financial Forecast
Revenue This Year
1.09M
Revenue Next Year
44.74M
from 1.09M
Increased by 3,993.60%
EPS This Year
-3.03
from -2.57
EPS Next Year
-3.08
from -3.03
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.8M | 167.8M | ||||
| Avg | 1.1M | 44.7M | ||||
| Low | n/a | 7.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 15,251.3% | ||||
| Avg | - | 3,993.6% | ||||
| Low | - | 537.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.71 | -2.09 | ||||
| Avg | -3.03 | -3.08 | ||||
| Low | -3.08 | -3.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.